Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25670600 | 0.80 | LMNA (0.35) | KDM4EMAPTNQO2 | |
| SCHEMBL24067384 | 0.79 | NTSR1 (0.47) | KDM4ESMN1; SMN2 | |
| SCHEMBL25670607 | 0.78 | KDM4E (0.35) | KDM4EHSD17B10RAD52RAB9ASMN1; SMN2 | |
| SCHEMBL12397284 | 0.74 | ALDH1A1 (0.44) | KDM4ESMN1; SMN2MAPTHPGDL3MBTL1 | |
| SCHEMBL24067370 | 0.73 | ALDH1A1 (0.40) | KDM4EHSD17B10RAB9ASMN1; SMN2HPGD | |
| SCHEMBL24067374 | 0.69 | NTSR1 (0.42) | KDM4ERAB9ASMN1; SMN2MAPTHPGD | |
| SCHEMBL25832927 | 0.68 | KDM4E (0.31) | KDM4ESMN1; SMN2 | |
| SCHEMBL14289087 | 0.67 | EGFR (0.40) | SMN1; SMN2MAPTNQO2 | |
| SCHEMBL10315754 | 0.65 | KMT2A (0.46) | KDM4EHSD17B10RAB9ASMN1; SMN2MAPT | |
| SCHEMBL12397282 | 0.64 | DYRK1A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-25 | — | — | US | disclosed |
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | CYANA THERAPEUTICS LLC | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11701371-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | KDM4E 3368/4885HSD17B10 3715/4885RAD52 299/4885 |
| US-20230190927-A1 | ENPP1 INHIBITORS AND METHODS OF MODULATING IMMUNE RESPONSE | ENPP1, STING1, ENPP3 | KDM4E 3971/4885HSD17B10 3317/4885RAD52 2135/4885 |
| US-11707471-B2 | ENPP1 inhibitors and their use for the treatment of cancer | ENPP1, ENPP3, ENTPD1 | KDM4E 3368/4885HSD17B10 3715/4885RAD52 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.